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Abstract  
 
Objective:  To describe growth during puberty in young people with vertically acquired HIV. 
Design: Pooled data from 12 paediatric HIV cohorts in Europe and Thailand. 
Methods: 1094 children initiating an NNRTI- or boosted PI-based regimen aged 1 to 10 years 
were included. Super Imposition by Translation And Rotation (SITAR) models described 
growth from age 8 years using 3 parameters (average height, timing and shape of the growth 
spurt), dependent on age and height-for-age z-score (HAZ) (World Health Organisation 
references) at ART initiation. Multivariate regression explored characteristics associated with 
these 3 parameters.  
Results: At ART initiation median age and HAZ was 6.4[IQR:2.8,9.0] years and -1.2[-2.3,-
0.2], respectively. Median follow-up was 9.1[6.9,11.4] years. In females, older age and lower 
HAZ at ART initiation were independently associated with a growth spurt which occurred 
0.41(95% CI 0.20,0.62) years later in children starting ART age 6-<11 years compared to 1-
<3 years and 1.50(1.21,1.78) years later in those starting with HAZ<-3 compared to HAZ≥-1. 
Later growth spurts in females resulted in continued height growth into later adolescence. In 
males starting ART with HAZ<-1, growth spurts were later in children starting ART in the 
oldest age group, but for HAZ≥-1 there was no association with age. Males and females who 
initiated ART with HAZ≥-1 maintained a similar height to the WHO reference mean.  
Conclusions: Stunting at ART initiation was associated with later growth spurts in females. 
Children  with HAZ≥-1 at ART initiation grew in height at the level expected in HIV 
negative children of a comparable age. 
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Introduction 
Although young people living with HIV are at risk for poor height growth[1], treatment with 
antiretroviral therapy (ART) improves growth, with strongest gains in those treated at a 
young age[2].  While initial catch-up growth on ART has been well described[2] there are 
less data on long term growth, particularly during adolescence.  
 
Delays in pubertal development have been reported in young people with HIV[3-7] with the 
onset of puberty[5] and sexual maturation[6] occurring 6 months later compared to HIV-
exposed uninfected young people (HEU). Earlier puberty in the general population is 
associated with being taller and having higher BMI throughout childhood[8], and poor 
growth in children with PHIV has been shown to account for much of the delay in reaching 
sexual maturity[6]. There is also evidence that children starting ART with low height-for-age 
z-scores experience delays in the onset of puberty independently of age at ART initiation[3].  
 
Poor growth during childhood can have implications for future health. Height velocity is 
associated with increased HIV replication[9] and progression to AIDS and death[10] with the 
association with death being independent of age, viral load and CD4 count[11]. The timing of 
puberty is also inversely associated with bone mass and density among HIV-negative 
adolescents[12] and delayed puberty may increase future risk of osteoporosis among young 
people with HIV, who themselves are at risk of poor bone health, either caused by HIV 
infection itself or prolonged exposure to ART[13].  Early growth failure has also been linked 
to poorer social and economic outcomes in later life in the general population[14]. 
 
In this study, statistical models which describe an individual’s growth in terms of mean 
height throughout adolescence, and timing and shape of the adolescent growth spurt were 
applied to longitudinal height measurements. The overall aim of this study was to explore the 
association between characteristics at ART initiation, in particular age and height-for-age z-
score, and growth during adolescence. 
 
Methods 
17 paediatric HIV cohorts from 15 countries contributed individual level data to the European 
Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) between September 2016 and 
March 2017 using a modified HICDEP protocol (www.hicdep.org). Pseudo-anonymised data 
on all children at participating clinics were included. All cohorts received approval from local 
and/or national ethical committees. Five cohorts from three countries (Italy, Ukraine and 
three from Russia) where height data were not routinely collected (each with <20% of 
children having a height measurement at ART initiation) were excluded. Children from the 
remaining 12 cohorts were eligible provided they initiated ART with ≥2 nucleoside reverse 
transcriptase inhibitors (NRTI) + a non-nucleoside reverse transcriptase inhibitor (NNRTI) or 
boosted protease inhibitor (bPI); were 1-10 years old at ART initiation; not known to have 
horizontally-acquired HIV; and aged ≥8 years at the end of follow-up. We excluded children 
initiating ART after age 11 years. For those initiating ART at an older age it would be 
difficult to distinguish between changes in growth occurring as a result of a pubertal growth 
spurt and as a result of initiating ART. Children with no height recorded at ART initiation 
and/or after 8 years of age were excluded.   
 
Height measurements were censored at the earliest of: 19th birthday, transfer to adult care, 
death or loss to follow-up.  Height and BMI were converted to height-for-age z-scores (HAZ) 
and BMI-for-age z-scores (zBMI), using the World Health Organization (WHO) Growth 
Standard for measurements when children were aged <5 years old[15] and the WHO 2007 
growth reference when aged 5-18 years [15, 16]. Data checks were carried out to detect 
implausible changes in height and/or HAZ. HAZ was categorised according to WHO 
definitions as: <-3 SD (severe stunting); -3 to < -2 SD (stunting); -2 to <-1 SD; and ≥-1 SD. 
zBMI was categorised as: <-2 SD (underweight); -2 to 1 SD (normal); >1 to 2 SD 
(overweight); and >2 SD (obese). HAZ and zBMI nearest to ART initiation (closest within 6 
months before to 1 month after) were considered baseline measurements.  
 
Other variables included were: sex, country (Thailand, UK/Ireland, Rest of Europe), age at 
ART initiation (1-2, 3-5 or 6 -10 years), initial ART regimen (PI, NNRTI), being born 
outside the country of the cohort (“born abroad”), and immunodeficiency at ART initiation 
classified using the WHO immunological classification: none (CD4% >35%, >30%, >25% or 
CD4 count >500cells/mm3 in children <1, 1-2, 3-4 and ≥5 years, respectively), mild (CD4% 
30-35%, 25-30%, 20-25% or CD4 count 350-499cells/mm3), advanced (CD4% 25-29%, 20-
24%, 15-19% or CD4 count 200-349 cells/mm3) or severe (CD4% <25%, <20%, 15-19% or 
in children >5 CD4 count <200cells/mm3 OR <15%)[17]. 
 
Statistical analysis 
Characteristics at ART initiation were summarised by HAZ category. Mean height at age 16 
years was summarised by age and HAZ at ART initiation and compared to the WHO 
reference height to quantify differences in height following the growth spurt. It was not 
possible to assess differences in final height as many adolescents transfer to adult care from 
age 16 years, ending follow-up in EPPICC.  
 
Height was modelled using Super Imposition by Translation And Rotation (SITAR) models 
[18]. SITAR was developed to model growth during childhood and adolescence and 
quantifies differences in growth via three parameters representing the timing and shape of the 
adolescent growth spurt, as well as average height. The models can explain up to 99% of the 
variation between individuals’ growth [18] and can be summarised as:  
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where the outcome yit is the height of individual i at age t and h() is a natural cubic spline of 
height over age. The parameters ܽ௜, ܾ௜ and ܿ௜ are participant specific random effects. ܽ௜ 
represents average height throughout adolescence; negative values indicate shorter height 
overall. ܾ௜ represents timing of the pubertal growth spurt; negative values indicate earlier 
puberty. ܿ௜ represents growth velocity, or the shape of the growth spurt; positive values 
indicate shorter growth spurts and a steeper growth velocity curve while negative values 
indicate the growth spurt occurs over a longer duration. Corresponding growth velocity 
curves can also be estimated as the first derivative of the modelled growth (height) curve.  
 
Age at peak height velocity (APHV) is correlated with timing of puberty and often used as a 
proxy for timing of maturation. It commonly occurs in girls in Tanner stage 2 or 3 and in 
Tanner stage 3 or 4 for boys[19, 20], though there is variation in timing across Tanner stages 
[19]. Differences in the timing of the growth spurt estimated using SITAR models have been 
shown to be highly correlated with APHV[18]. 
 
All height measurements (in centimetres) from age 8 (or start of ART if after 8th birthday) to 
18 years were included. Age and HAZ at ART initiation were added to the SITAR model as 
fixed effects which could influence the mean of a, b and c. Thus the estimated random effects 
ܽ௜, ܾ௜ and ܿ௜ represent the individual differences in average height, timing and shape of the 
growth spurt not associated with differences in age or height at ART initiation.  Models were 
fitted separately to males and females using a spline with 6 degrees of freedom. Log 
transformations of both age and height [18] were considered but the untransformed data 
provided the best fit.  Interactions between baseline height and age were added where 
appropriate (model comparison carried out using Bayes Information Criteria (BIC)).  
 
To explore other factors (sex, country, initial ART regimen, WHO immunological 
classification, zBMI at ART initiation) associated with growth after allowing for differences 
in baseline age and height, the estimated ܽ௜, ܾ௜ and ܿ௜ random effects from the SITAR model 
were analysed using multivariable linear regression.  Interactions between each of the factors 
and sex and between immunological classification and HAZ and age at ART initiation were 
considered. A second model was fitted including zBMI at age 8 years instead of at ART 
initiation.  
 
Modelling was repeated in countries where >5% of children were born abroad and >5% born 
in the country (UK & Ireland, Spain and Netherlands) to explore differences between those 
born abroad and those born in the cohort country.  Sensitivity analyses were carried out in 
which i) models were fitted separately to children from Thailand and elsewhere ii) Thai 
specific growth reference data were used for Thai children[21], and iii) children starting ART 
after age 8 years were excluded.  
Analyses were carried out using STATA/IC 15.1 and the SITAR package[22] in R v3.3.3. 
 
Results 
Patient characteristics 
In total 1943 young people with HIV initiated ART on an eligible regimen age 1- 10 years 
and were ≥8 years at end of follow up (Figure 1). After excluding those with missing baseline 
height (n=721) and/or height after age 8 years (n=202), we included 1094 children in the 
analysis. Children excluded due to missing height data were more likely to be from countries 
other than Thailand or UK/Ireland, be born abroad, and be younger at ART initiation than 
those who were included (Supplementary Table 1). The 1094 included children were 
followed-up for a median of 9.1[6.9,11.4] years after ART initiation. During this time 37,325 
height measurements were recorded with a median of 32[19, 46] per child, of which 25,458 
(median 21[11,32]) were from age  8 years onwards. The median time between height 
measurements was 2.8[1.4,3.9] months, with some variation by cohort ranging from every 
1.8[1.0,2.8] months in Thailand to 8.3[4.7,11.3] months in Greece. 
 
At ART initiation median HAZ was -1.2[-2.3,-0.2] and age was 6.4[2.8,9.0] years. 
Characteristics of children at ART initiation, stratified by baseline HAZ, are described in 
Table 1. More severe stunting was associated with residence in Thailand, not being born 
abroad, initiating on an NNRTI based regimen, earlier calendar year of ART initiation, higher 
viral load, more severe immunodeficiency and lower zBMI at ART initiation. 
 
At the end of the study 493(45%) children had reached their 16th birthday while still in 
paediatric care (Figure 1); of whom 463(94%) had their height recorded within 6 months of 
their birthday. Children who survived to age 16 years but were no longer in follow up in 
paediatric care were more likely to reside in Thailand and start ART at a younger age. At age 
16 years the mean (standard deviation) heights of males and females were 166(8.7)cm and 
158(6.9)cm respectively, significantly shorter than the WHO reference mean height of 
173(7.8)cm for males and 163(6.8)cm for females (both p<0.001) (Supplementary Table 2).  
 
Associations between age and HAZ at ART initiation and growth from age 8 years 
Results from the SITAR models are available in Supplementary Table 3. Estimated mean 
height and corresponding growth velocity curves stratified by HAZ and by age are 
summarised in Figure 2A and 2B, respectively, for females and Figure 3A and 3B for males. 
 
In females, across each of the baseline HAZ groups (Figure 2Ai-iv), children starting ART in 
the oldest age group had growth spurts on average 0.41(95% CI 0.20,0.62) years later than 
those starting ART in the youngest age group.  Across the baseline age groups (Figure 2Bi-
iii), females starting ART with low HAZ had later growth spurts; there was a 1.50(1.21,1.78) 
year delay in those with baseline HAZ<-3 compared to baseline HAZ≥-1. The effect of this 
delay on overall height can be seen in Figures 2L-N; the differences in height are smaller 
from age 16 onwards (after the growth spurt) than at age 8. 
 
In males, the association between baseline age and the timing of the growth spurt differed by 
baseline HAZ (Figure 3Ai-iv); there was no significant difference by age in males who 
started ART with HAZ≥-1 (Figure 3Ai). In males with baseline HAZ of -2 to <-1 (Figure 
3Aii), the growth spurt was 0.96(0.19,1.72) years later in those starting ART in the oldest 
compared to youngest age group. Similarly, for a baseline HAZ of -3 to <-2 (Figure 3Aiii) 
the corresponding delay in those starting ART in the oldest age group was 0.92(0.17,1.66) 
years, and for baseline HAZ<-3 it was 0.42(-0.32,1.16) years (Figure 3Aiv). The timing of 
the growth spurt in males did not differ significantly by baseline HAZ (Figure 3Bi-iii).  
 
Females (Figure 2Bi) and males (Figure 3Bi), who started treatment with a baseline HAZ≥-1 
maintained a similar mean height to the WHO reference, regardless of baseline age. 
 
Other factors associated with growth from age 8 years 
Characteristics associated with variations in growth that remained after adjusting for 
differences in baseline HAZ and age are summarised in Table 2.  Young people from 
Thailand were smaller throughout adolescence than those from other countries, but did not 
differ in the timing of the growth spurt.  The shape of the growth spurt differed by country 
and was shorter in children from the UK and Ireland than elsewhere. Lower zBMI at ART 
initiation was significantly associated with a later growth spurt (a one SD decrease was 
associated with a 0.07(0.02,0.11) year delay in the growth spurt). In a second model (data not 
shown)  a one SD decrease in zBMI at age 8 years was  associated with a 0.16(0.09,0.22) 
year delay in the timing of the growth spurt, while other parameters did not change 
substantially. There was no evidence of any interactions.  
 
In subgroup analysis (n=545) there was a significant interaction between gender and being 
born abroad on timing of the growth spurt (p=0.038).  Females born abroad experienced a 
growth spurt 0.24(0.02,0.46) years earlier than those born in the cohort country; while there 
was no association in males.  However, after adjusting for zBMI at age 8, the association was 
no longer significant (growth spurt for females  born abroad was 0.18(-0.05,0.42) years 
earlier) 
 
In the three sensitivity analyses where 1) models were fitted separately to children from 
Thailand and elsewhere, 2) Thai specific reference data were used for Thai children and 3) 
children starting ART age≥8 years were excluded, overall conclusions were unchanged (data 
not shown). 
  
Discussion 
In this study we described growth throughout adolescence in a large cohort of young people 
with vertically acquired HIV in Europe and Thailand. Although all adolescents in the study 
initiated ART before age 11 years, growth deficits remained throughout adolescence. Only 
children with HAZ≥-1 when starting ART were able to achieve a similar height to the WHO 
reference at age 16 years, suggesting that for others, catch up growth associated with being 
on ART long term was not sufficient to restore height to what would be expected in an HIV-
negative population.  
 
We observed an association between older age at ART initiation and later growth spurts in 
males (with HAZ <-1 at ART initiation) and females, in line with findings from the 
Antiretroviral research for Watoto (ARROW) where attainment of each tanner stage and 
onset of menarche was delayed in those starting ART at older ages[3]. We also observed an 
association between stunting and later growth spurts, but only in females. The potential role 
of anthropometric parameters in early childhood on growth during puberty was highlighted in 
a study of 2539 young people with vertically acquired HIV and HIV exposed uninfected 
(HEU) young people from the USA[6]. Young people living with HIV reached sexual 
maturity on average 6 months later than the HEU group, but differences in HAZ prior to 
puberty accounted for up to 98% of the delay in males and (together with zBMI) 74% in 
females, suggesting much of the delay may be attributable to earlier poor growth [6]. Low 
HAZ at ART initiation was also associated with delayed attainment of all Tanner stages in 
males and females, and menarche in females, independently of age at ART initiation in the 
ARROW trial [3]. However, in males, the delay was reduced in those who had the greatest 
initial gains in CD4 after starting ART, but there was no similar association in females. 
Undernutrition early in life was also found to have a stronger association with adult height in 
females than males in the Netherlands [23]. While this suggests females may be more 
sensitive to impairments early in life, and prior to ART, the mechanism underlying potential 
gender differences remains to be explained.  
After accounting for HAZ and age at ART initiation we found no association between WHO 
immunological status or viral load at ART initiation and growth. Similarly, the ARROW trial 
found immune suppression prior to ART was not associated with delayed puberty or 
menarche[3]. Other studies have also reported a lack of association between clinical status at 
start of puberty and age at onset[4, 7].  However, in young people in the USA, low CD4 and 
high VL at first pubertal assessment were associated with later pubertal onset. Among males, 
prior CDC C, low nadir CD4% or high peak VL were also associated with later puberty[5]. 
However many of these young people initiated ART on mono or dual therapy and are likely 
to have substantially different treatment histories compared to our study.  
 
We found zBMI at ART initiation and age 8 to be associated with the timing of the growth 
spurt, with no evidence of a difference between males and females.  We also observed that 
females born abroad experienced an earlier pubertal growth spurt than females born in the 
cohort country but the differences in the timing of the growth spurt reduced after adjusting 
for zBMI at age 8. In females a relationship between low BMI and delayed puberty has been 
found in multiple studies[8] and rapid weight gain prior to puberty also linked to early 
onset[24]. Differences between young people born abroad and those born in the country may 
therefore be explained by periods of more rapid weight gain in children arriving from abroad, 
the majority from Africa, compared to those born in the country.  
 
This study had several limitations; as with all observational studies our findings on the 
association between age and HAZ at ART initiation and growth should not be over 
interpreted or assumed to be causative. At ART initiation stunting was strongly correlated 
with immunosuppression, viral load and zBMI and may be a marker for poor immunological 
status and other impairments. Children starting ART at older ages represent a group who 
have survived without treatment and possibly with limited access to care and so may be 
subject to a survivor bias. Had ART initiation been delayed in those who started at a young 
age, the observed delay in the growth spurt associated with starting ART at an older age may 
have been less in this group who would also have been more likely to have access to health 
care and regular monitoring.  Nonetheless the findings provide insight in to growth patterns 
among children presenting to care and starting ART at different ages.  
 
Inclusion criteria applied also leads to the potential for selection bias. We excluded children 
with missing height data. Multiple imputation was not possible since other data, such as 
immunological and virological status, at ART initiation, likely to be strong predictors of 
baseline height were missing in more than half of the children with missing heights. We 
excluded young people from Russia, Ukraine and Italy where height data were not routinely 
recorded. Further the cohorts included in EPPICC range from national coverage to city 
hospitals leading to potential for bias where children treated in large city hospitals are not 
representative of others in the country.  Our analyses were restricted to children aged 1-10 
years at ART initiation. The number of infants initiating ART under age 1 year was small, 
with high rates of missing baseline data.. A further limitation is the lack of quantitative 
measures of pubertal status such as Tanner stage and date of onset of menarche, which is not 
routinely collected by the majority of participating cohorts. However, differences in timing of 
the growth spurt are likely to be indicative of differences in timing of onset of puberty. 
 
Finally, we used the WHO growth standard[15] and  growth reference[16] to derive z-scores 
at ART initiation. While the WHO growth standards were developed to assess growth 
globally, children from Thailand were significantly shorter than those residing in Europe and 
WHO reference may overestimate stunting as compared to Thailand’s own national growth 
reference[25] . However, in sensitivity analyses, using Thai reference data we did not find 
any difference in the associations between baseline HAZ and growth during adolescence..  
 
Despite these limitations, the study has several strengths. The collaborative nature of the 
study provides a rich source of longitudinal height measurements from a large sample of 
young people living with HIV followed during childhood and adolescence and the use of 
SITAR models provides insight into growth during puberty in the absence of quantitative 
measures of pubertal status.  
 
In summary, we have shown that children who initiate ART at younger ages are taller. 
Children who initiate ART with a ‘normal’ height for age z-score (HAZ≥-1) remained with a 
“normal” height throughout adolescence.  Those who initiated ART stunted or severely 
stunted were less likely to achieve ‘normal’ height.  We also demonstrated that in females, 
regardless of age at ART initiation, stunting at time of initiation was associated with a later 
pubertal growth spurt, and this continued growth into later adolescents may allow those most 
severely stunted to catch-up somewhat. However, longer-term follow-up is required to 
understand the potential implications of delayed pubertal growth on outcomes in later life. 
 
Acknowledgements 
We thank all the patients for their participation in these cohorts, and the staff members who 
cared for them.  
Author contributors: Writing Group (consisting of Project Team first (ordered alphabetically 
by name except for the first and last author), and also other Writing Group members (ordered 
alphabetically by cohort name)): 
Project Team: Siobhan Crichton (EPPICC statistician), Eric Belfrage (Karolinska Institutet 
and University Hospital, Stockholm, Sweden), Intira Jeanne Collins (Collaborative HIV 
Paediatric Study (CHIPS), UK and Ireland ), Katja Doerholt (Collaborative HIV Paediatric 
Study (CHIPS), UK and Ireland), Ali Judd (co-lead of EPPICC), Sophie Le Coeur (Thailand 
Program for HIV Prevention and Treatment (PHPT) Study Group, Thailand), Vana Spoulou 
(Greece Cohort, Greece), Ruth Goodall (EPPICC senior statistician). 
Other Writing Group members: Henriette Scherpbier, Colette Smit (ATHENA paediatric 
cohort, Netherlands); Tessa Goetghebuer (Hospital St Pierre Cohort, Brussels, Belgium); 
Diana M. Gibb (Collaborative HIV Paediatric Study (CHIPS) and National Study of HIV in 
Pregnancy and Childhood (NSHPC), UK & Ireland); Antoni Noguera (CoRISPE-CAT, 
Catalonia cohort, Spain) Maria Luisa Navarro, Jose Tomas Ramos (CoRISPE-S, rest of Spain 
cohort, Spain); Luisa Galli (Italian Register for HIV infection in children, Italy); Carlo 
Giaquinto, Claire Thorne (Paediatric European Network for the Treatment of AIDS 
(PENTA), Italy); Santa Ansone (Latvian cohort, Latvia); Magdalena Marczynska (Polish 
paediatric cohort, Poland); Liubov Okhonskaia (Republican Hospital of Infectious Diseases, 
St Petersburg, Russia); Begoña Martinez de Tejada (Swiss Mother and Child HIV Cohort 
Study, Switzerland); Gonzague Jourdain, Luc Decker (Thailand Program for HIV Prevention 
and Treatment (PHPT) Study Group, Thailand); Luminita Ene (“Victor Babes” Hospital 
Cohort, Romania). 
  
APPENDIX: COLLABORATING COHORTS 
Belgium: Hospital St Pierre Cohort, Brussels: Tessa Goetghebuer, MD, PhD; Marc Hainaut, 
MD PhD; Evelyne Van der Kelen, Research nurse; Marc Delforge, data manager. 
Greece: Greek cohort: Vana Spoulou. 
Italy: Italian Register for HIV infection in Children.  Coordinators: Maurizio de Martino 
(Florence), Pier Angelo Tovo (Turin). Participants: Osimani Patrizia (Ancona), Domenico 
Larovere (Bari), Maurizio Ruggeri (Bergamo), Giacomo Faldella, Francesco Baldi (Bologna) 
Raffaele Badolato (Brescia), Carlotta Montagnani, Elisabetta Venturini, Catiuscia Lisi 
(Florence), Antonio Di Biagio, Lucia Taramasso (Genua), Vania Giacomet, Paola Erba, 
Susanna Esposito, Rita Lipreri, Filippo Salvini, Claudia Tagliabue (Milan), Monica Cellini 
(Modena), Eugenia Bruzzese, Andrea Lo Vecchio (Naples), Osvalda Rampon, Daniele Donà 
(Padua), Amelia Romano (Palermo), Icilio Dodi (Parma), Anna Maccabruni (Pavia), Rita 
Consolini (Pisa), Stefania Bernardi, Hyppolite Tchidjou Kuekou, Orazio Genovese (Rome), 
Paolina Olmeo (Sassari), Letizia Cristiano (Taranto), Antonio Mazza (Trento), Clara 
Gabiano, Silvia Garazzino (Turin), Antonio Pellegatta (Varese) 
Latvia:  Latvian Cohort (Santa Ansone) 
 Netherlands: The ATHENA database is maintained by Stichting HIV Monitoring and 
supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the 
Centre for Infectious Disease Control of the National Institute for Public Health and the 
Environment.  
CLINICAL CENTRES (PAEDIATRIC CARE) 
Emma Kinderziekenhuis, Amsterdam, University Medical Centers: HIV treating 
physicians: D. Pajkrt, H.J. Scherpbier. HIV nurse consultants: A.M. Weijsenfeld, C.G de 
Boer. HIV clinical virologists/chemists: S. Jurriaans, N.K.T. Back, H.L. Zaaijer, B. Berkhout, 
M.T.E. Cornelissen, C.J. Schinkel, K.C.wolthers. Erasmus MC–Sophia, Rotterdam: HIV 
treating physicians: P.L.A. Fraaij, A.M.C. van Rossum, C.L. Vermont. HIV nurse 
consultants: L.C. van der Knaap, E.G. Visser. HIV clinical virologists/chemists: C.A.B. 
Boucher, M.P.G Koopmans, J.J.A van Kampen, S.D. Pas. Radboudumc, Nijmegen: HIV 
treating physicians: S.S.V. Henriet, M. van de Flier, K. van Aerde. HIV nurse consultants: R. 
Strik-Albers. HIV clinical virologists/chemists: J. Rahamat-Langendoen, F.F. Stelma. 
Universitair Medisch Centrum Groningen, Groningen: HIV treating physicians: E.H. 
Schölvinck. HIV nurse consultants: H. de Groot-de Jonge. HIV clinical virologists/chemists: 
H.G.M. Niesters, C.C. van Leer-Buter, M. Knoester. Wilhelmina Kinderziekenhuis, UMC 
Utrecht, Utrecht: HIV treating physicians: L.J. Bont, S.P.M. Geelen, T.F.W. Wolfs. HIV 
nurse consultants: N. Nauta. HIV clinical virologists/chemists: R. Schuurman, F. Verduyn-
Lunel, A.M.J. Wensing. 
COORDINATING CENTRE  
Director: P. Reiss. Deputy director: S. Zaheri. Data analysis: D.O. Bezemer, A.I. van 
Sighem, C. Smit, F.W.M.N. Wit. Data management and quality control: M. Hillebregt, A. de 
Jong, T. Woudstra. Data monitoring: D. Bergsma, S. Grivell, R. Meijering, M. Raethke, T. 
Rutkens. Data collection: L. de Groot, M. van den Akker, Y. Bakker, M. Bezemer, A. El 
Berkaoui, J. Geerlinks, J. Koops, E. Kruijne, C. Lodewijk, E. Lucas, R. van der Meer, L. 
Munjishvili, F. Paling, B. Peeck, C. Ree, R. Regtop, Y. Ruijs, L. van de Sande, M. Schoorl, 
P. Schnörr, E. Tuijn, L. Veenenberg, S. van der Vliet, A. Wisse, E.C. Witte. Patient 
registration: B. Tuk. 
Poland: Polish paediatric cohort: Head of the team: Prof Magdalena Marczyńska, MD, PhD.  
Members of the team: Jolanta Popielska, MD, PhD; Maria Pokorska-Śpiewak, MD, PhD; 
Agnieszka Ołdakowska, MD, PhD; Konrad Zawadka, MD, PhD; Urszula Coupland, MD, 
PhD.  Administration assistant: Małgorzata Doroba.  Affiliation: Medical University of 
Warsaw, Poland, Department of Children’s Infectious Diseases; Hospital of Infectious 
Diseases in Warsaw, Poland. 
Romania: "Victor Babes" Hospital Cohort, Bucharest: Dr Luminita Ene. 
Russia: Federal State-owned Institution "Republican Clinical Infectious Diseases Hospital" 
of the Ministry of Health of the Russian Federation, St Petersburg: Liubov Okhonskaia, 
Evgeny Voronin, Milana Miloenko, Svetlana Labutina 
Spain: CoRISPE-cat, Catalonia: financial support for CoRISPE-cat was provided by the 
Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida.  
Members: Hospital Universitari Vall d’Hebron, Barcelona (Pere Soler-Palacín, Maria 
Antoinette Frick and Santiago Pérez-Hoyos (statistician)), Hospital Universitari del Mar, 
Barcelona (Antonio Mur, Núria López), Hospital Universitari Germans Trias i Pujol, 
Badalona (María Méndez), Hospital Universitari JosepTrueta, Girona (Lluís Mayol), Hospital 
Universitari Arnau de Vilanova, Lleida (Teresa Vallmanya), Hospital Universitari Joan 
XXIII, Tarragona (Olga Calavia), Consorci Sanitari del Maresme, Mataró (Lourdes García), 
Hospital General de Granollers (Maite Coll), Corporació Sanitària Parc Taulí, Sabadell 
(Valentí Pineda), Hospital Universitari Sant Joan, Reus (Neus Rius), Fundació Althaia, 
Manresa (Núria Rovira), Hospital Son Espases, Mallorca (Joaquín Dueñas) and Hospital Sant 
Joan de Déu, Esplugues (Clàudia Fortuny, Antoni Noguera-Julian). 
Spain: CoRISPE-S and Madrid cohort: María José Mellado, Luis Escosa, Milagros García 
Hortelano, Talía Sainz (Hospital La Paz);María Isabel González- Tomé, Pablo Rojo, Daniel 
Blázquez (Hospital Doce de Octubre, Madrid); José Tomás Ramos (Hospital Clínico San 
Carlos, Madrid); Luis Prieto, Sara Guillén (Hospital de Getafe); María Luisa Navarro, Jesús 
Saavedra, Mar Santos, Mª Angeles Muñoz, Beatriz Ruiz, Carolina Fernandez  Mc Phee, 
Santiago Jimenez de Ory,Susana Alvarez (Hospital Gregorio Marañón); Miguel Ángel Roa 
(Hospital de Móstoles); José Beceiro (Hospital Príncipe de Asturias, Alcalá de Henares); 
Jorge Martínez (Hospital Niño Jesús, Madrid); Katie Badillo (Hospital de Torrejón); Miren 
Apilanez (Hospital de Donostia, San Sebastián); Itziar Pocheville (Hospital de Cruces, 
Bilbao);  Elisa Garrote (Hospital de Basurto, Bilbao); Elena Colino (Hospital Insular Materno 
Infantil, Las Palmas de Gran Canaria); Jorge Gómez Sirvent (Hospital Virgen de la 
Candelaria, Santa Cruz de Tenerife); Mónica Garzón, Vicente Román (Hospital de 
Lanzarote); Abián Montesdeoca, Mercedes Mateo (Complejo Universitario de Canarias, La 
Laguna-Tenerife),María José Muñoz, Raquel Angulo (Hospital de Poniente, El Ejido); Olaf 
Neth, Lola Falcón (Hospital Virgen del Rocio, Sevilla); Pedro Terol (Hospital Virgen de la 
Macarena, Sevilla); Juan Luis Santos (Hospital Virgen de las Nieves, Granada); David 
Moreno (Hospital Carlos Haya, Málaga); Francisco Lendínez (Hospital de Torrecárdenas, 
Almería); Ana Grande (Complejo Hospitalario Universitario Infanta Cristina, Badajoz); 
Francisco José Romero (Complejo Hospitalario de Cáceres); Carlos Pérez (Hospital de 
Cabueñes, Gijón); Miguel Lillo (Hospital de Albacete); Begoña Losada (Hospital Virgen de 
la Salud, Toledo); Mercedes Herranz (Hospital Virgen del Camino, Pamplona); Matilde 
Bustillo, Carmelo Guerrero (Hospital Miguel Servet, Zaragoza); Pilar Collado (Hospital 
Clínico Lozano Blesa, Zaragoza); José Antonio Couceiro (Complejo Hospitalario de 
Pontevedra); Amparo Pérez, Ana Isabel Piqueras, Rafael Bretón, Inmaculada Segarra 
(Hospital La Fe, Valencia); César Gavilán (Hospital San Juan de Alicante); Enrique Jareño 
(Hospital Clínico de Valencia); Elena Montesinos (Hospital General de Valencia); Marta 
Dapena (Hospital de Castellón); Cristina Álvarez (Hospital Marqués de Valdecilla, 
Santander); Ana Gloria Andrés (Hospital de León); Víctor Marugán, Carlos Ochoa (Hospital 
de Zamora); Santiago Alfayate, Ana Isabel Menasalvas (Hospital Virgen de la Arrixaca, 
Murcia); Elisa de Miguel (Complejo Hospitalario San Millán-San Pedro, Logroño) and 
Paediatric HIV-BioBank integrated in the Spanish AIDS Research Network and collaborating 
Centers. 
Funding: This work has been partially funded by the Fundación para la Investigación y 
Prevención de SIDA en España (FIPSE) (FIPSE 3608229/09 , FIPSE 240800/09, FIPSE 
361910/10),  Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de 
Salud Carlos III (ISCIII) (RD12/0017/0035 and RD12/0017/0037), project as part of the Plan 
R+D+I and cofinanced by ISCIII- Subdirección General de Evaluación and Fondo Europeo 
de Desarrollo Regional (FEDER),Mutua Madrileña 2012/0077, Gilead Fellowship 
2013/0071, FIS PI15/00694 ,CoRISpe (RED RIS RD06/0006/0035 y RD06/0006/0021).  
Sweden: Karolinska University Hospital, Stockholm (Lars Naver, Sandra Soeria-Atmadja, 
Vendela Hagås). 
Switzerland: Members of the Swiss HIV Cohort Study (SHCS) and the Swiss Mother and 
Child HIV Cohort Study: Aebi-Popp K, Anagnostopoulos A, Asner S, Battegay M, Baumann 
M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, 
Duppenthaler A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Francini K, Furrer H, Fux 
CA, Grawe C, Günthard HF (President of the SHCS), Haerry D (deputy of "Positive 
Council"), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Huber M, Kahlert CR (Chairman of 
the Mother & Child Substudy), Kaiser L, Keiser O, Klimkait T, Kottanattu L, Kouyos 
RD, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, 
Müller N, Nicca D, Paioni P, Pantaleo G, Perreau M, Polli Ch, Rauch A (Chairman of the 
Scientific Board), Rudin C, Scherrer AU (Head of Data Centre), Schmid P, Speck R, Stöckle 
M (Chairman of the Clinical and Laboratory Committee), Tarr P, Thanh Lecompte M, Trkola 
A, Vernazza P, Wagner N, Wandeler G, Weber R, Wyler CA, Yerly S. Funding: This study 
has been financed within the framework of the Swiss HIV Cohort Study, supported by the 
Swiss National Science Foundation (grant #177499).  
Thailand: Program for HIV Prevention & Treatment (PHPT). Participating hospitals: 
Lamphun: Pornpun Wannarit; Phayao Provincial Hospital: Pornchai Techakunakorn; 
Chiangrai Prachanukroh: Rawiwan Hansudewechakul; Chiang Kham: Vanichaya 
Wanchaitanawong; Phan: Sookchai Theansavettrakul; Mae Sai: Sirisak Nanta; Prapokklao: 
Chaiwat Ngampiyaskul; Banglamung: Siriluk Phanomcheong; Chonburi: Suchat 
Hongsiriwon; Rayong: Warit Karnchanamayul; Bhuddasothorn Chacheongsao: Ratchanee 
Kwanchaipanich; Nakornping: Suparat Kanjanavanit; Somdej Prapinklao: Nareerat 
Kamonpakorn, Maneeratn Nantarukchaikul; Bhumibol Adulyadej: Prapaisri Layangool, 
Jutarat Mekmullica; Pranangklao: Paiboon Lucksanapisitkul, Sudarat Watanayothin; 
Buddhachinaraj: Narong Lertpienthum; Hat Yai: Boonyarat Warachit; Regional Health 
Promotion Center 6, Khon Kaen: Sansanee Hanpinitsak; Nong Khai: Sathit Potchalongsin; 
Samutsakhon: Pimpraphai Thanasiri, Sawitree Krikajornkitti; Phaholpolphayuhasena: 
Pornsawan Attavinijtrakarn; Kalasin: Sakulrat Srirojana; Nakhonpathom: Suthunya 
Bunjongpak; Samutprakarn: Achara Puangsombat; Mahasarakam: Sathaporn Na-Rajsima; 
Roi-et: Pornchai Ananpatharachai; Sanpatong: Noppadon Akarathum; Vachira Phuket: 
Weerasak Lawtongkum; Chiangdao: Prapawan Kheunjan, Thitiporn Suriyaboon, Airada 
Saipanya. 
Data management team: Kanchana Than-in-at, Nirattiya Jaisieng, Rapeepan Suaysod, 
Sanuphong Chailoet, Naritsara Naratee, and Suttipong Kawilapat. 
UK & Ireland: Collaborative HIV Paediatric Study (CHIPS): CHIPS is funded by the NHS 
(London Specialised Commissioning Group) and has received additional support from 
Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Roche, Abbott, and Gilead 
Sciences.  The MRC Clinical Trials Unit at UCL is supported by the Medical Research 
Council (https://www.mrc.ac.uk) programme number MC_UU_12023/26.  
CHIPS Steering Committee: Hermione Lyall (chair), Alasdair Bamford, Karina Butler, 
Katja Doerholt, Conor Doherty, Caroline Foster, Kate Francis, Ian Harrison, Julia Kenny, 
Nigel Klein, Gillian Letting, Paddy McMaster, Fungai Murau, Edith Nsangi, Helen Peters, 
Katia Prime, Andrew Riordan, Fiona Shackley,  Delane Shingadia, Sharon Storey, Claire 
Thorne, Gareth Tudor-Williams, Anna Turkova, Steve Welch. MRC Clinical Trials Unit: 
Intira Jeannie Collins, Claire Cook, Siobhan Crichton, Donna Dobson, Keith Fairbrother, 
Diana M. Gibb, Lynda Harper, Ali Judd, Marthe Le Prevost, Nadine Van Looy. National 
Study of HIV in Pregnancy and Childhood, UCL: Helen Peters, Claire Thorne.  
Participating hospitals: Republic of Ireland: Our Lady's Children’s Hospital Crumlin, 
Dublin: K Butler, A Walsh.  UK: University Hospitals Birmingham NHS Foundation Trust, 
Birmingham:  L Thrasyvoulou , S Welch; University Hospitals Bristol NHS Foundation 
Trust, Bristol: J Bernatoniene,  F Manyika ; Calderdale and Huddersfield NHS Foundation 
Trust, Halifax: G Sharpe; Derby Teaching Hospitals NHS Foundation Trust: B Subramaniam; 
Middlesex: K Sloper; East Sussex Healthcare NHS Trust, Eastbourne: K Fidler, Glasgow 
Royal Hospital for Children, Glasgow: R Hague, V Price; Great Ormond Street Hospital for 
Children NHS Foundation Trust, London: M Clapson, J Flynn,  A Cardoso M Abou – 
Rayyah, N Klein,  D Shingadia; Homerton University Hospital NHS Foundation Trust, 
London: D Gurtin, Oxford University Hospitals NHS Foundation Trust, Oxford:  S Yeadon , 
S Segal; King's College Hospital NHS Foundation Trust, London: C Ball, S Hawkins; Leeds 
Teaching Hospitals NHS Trust, Leeds:   M Dowie; University Hospitals of Leicester NHS 
Trust, Leicester: S Bandi,  E Percival ; Luton and Dunstable Hospital NHS Foundation Trust, 
Luton: M Eisenhut; K Duncan, S Clough; Milton Keynes General University Hospital NHS 
Foundation Trust , Milton Keynes: Dr L Anguvaa, S Conway, Newcastle upon Tyne 
Hospitals NHS Foundation Trust, Newcastle: T Flood, A Pickering; The Pennine Acute 
Hospitals NHS Trust, Manchester: P McMaster C Murphy; North Middlesex University 
Hospital NHS Trust, London: J Daniels, Y Lees; Northampton General Hospital NHS Trust, 
Northampton:  F Thompson; London North West Healthcare NHS Trust, Middlesex; B  
Williams, S Pope;  Nottingham University Hospitals NHS Trust, Nottingham: L Cliffe, A 
Smyth, S Southall; Portsmouth Hospitals NHS Trust, Portsmouth:  A  Freeman;  Raigmore 
Hospital, Inverness: H Freeman; Royal Belfast Hospital for Sick Children, Belfast: S 
Christie;  Royal Berkshire NHS Foundation Trust, Reading: A Gordon; Royal Children’s 
Hospital, Aberdeen: D Rogahn L Clarke;  Royal Edinburgh Hospital for Sick Children, 
Edinburgh: L Jones, B Offerman; Royal Free NHS Foundation Trust, London: M Greenberg ; 
Alder Hey Children's NHS Foundation Trust , Liverpool: C Benson, A Riordan;  Sheffield 
Children's NHS Foundation Trust, Sheffield: L Ibberson, F Shackley; University Hospital 
Southampton NHS Foundation Trust, Southampton: SN Faust, J Hancock; St George's 
University Hospitals NHS Foundation Trust, London: K Doerholt, , K Prime, M Sharland, S 
Storey; Imperial College Healthcare NHS Trust, London: H Lyall, C Monrose, P Seery, G 
Tudor-Williams; Guy's and St Thomas' NHS Foundation Trust, London: , E Menson, A 
Callaghan;   University Hospitals of North Midlands NHS Trust, Stoke On Trent: A 
Bridgwood, P McMaster; University Hospital of Wales, Cardiff:  J Evans, E Blake; NHS 
Frimley Health Foundation Trust, Slough: A Yannoulias. 
  
References 
1. Williams PL, Jesson J. Growth and pubertal development in HIV-infected adolescents. 
Current Opinion in HIV and AIDS 2018; 13(3):179-186. 
2. McGrath CJ, Diener L, Richardson BA, Peacock-Chambers E, John-Stewart GC. Growth 
Reconstitution following Antiretroviral Therapy and Nutrition Supplementation: 
Systematic Review and Meta-Analysis. AIDS 2015; 29(15):2009. 
3. Szubert AJ, Musiime V, Bwakura-Dangarembizi M, Nahirya-Ntege P, Kekitiinwa A, Gibb 
DM, et al. Pubertal development in HIV-infected African children on first-line 
antiretroviral therapy. AIDS 2015; 29(5):609. 
4. McHugh G, Rylance J, Mujuru H, Nathoo K, Chonzi P, Dauya E, et al. Chronic 
morbidity among older children and adolescents at diagnosis of HIV infection. Journal 
of Acquired Immune Deficiency Syndromes 2016; 73(3):275. 
5. Williams PL, Abzug MJ, Jacobson DL, Wang J, Van Dyke RB, Hazra R, et al. Pubertal 
onset in HIV-infected children in the era of combination Antiretroviral Treatment. 
AIDS 2013; 27(12):1959. 
6. Bellavia A, Williams PL, DiMeglio LA, Hazra R, Abzug MJ, Patel K, et al. Delay in 
sexual maturation in perinatally HIV-infected youths is mediated by poor growth. AIDS 
2017; 31(9):1333-1341. 
7. de Martino M, Tovo P-A, Galli L, Gabiano C, Chiarelli F, Zappa M, et al. Puberty in 
perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS 2001; 
15(12):1527-1534. 
8. Willemsen RH, Dunger DB. Normal variation in pubertal timing: genetic determinants 
in relation to growth and adiposity. In: Puberty from Bench to Clinic: Karger Publishers; 
2016. pp. 17-35. 
9. Arpadi SM, Cuff PA, Kotler DP, Wang J, Bamji M, Lange M, et al. Growth velocity, fat-
free mass and energy intake are inversely related to viral load in HIV-infected children. 
The Journal of Nutrition 2000; 130(10):2498-2502. 
10. Benjamin Jr DK, Miller WC, Benjamin DK, Ryder RW, Weber DJ, Walter E, et al. A 
comparison of height and weight velocity as a part of the composite endpoint in 
pediatric HIV. AIDS 2003; 17(16):2331-2336. 
11. Chantry CJ, Byrd RS, Englund JA, Baker CJ, MCKINNEY JR RE. Growth, survival 
and viral load in symptomatic childhood human immunodeficiency virus infection. The 
Pediatric Infectious Disease Journal 2003; 22(12):1033-1038. 
12. Gilsanz V, Chalfant J, Kalkwarf H, Zemel B, Lappe J, Oberfield S, et al. Age at onset of 
puberty predicts bone mass in young adulthood. The Journal of Pediatrics 2011; 
158(1):100-105. e102. 
13. Eckard AR, Mora S. Bone health in HIV-infected children and adolescents. Curr Opin 
HIV AIDS 2016; 11(3):294-300. 
14. Hoddinott J, Behrman JR, Maluccio JA, Melgar P, Quisumbing AR, Ramirez-Zea M, et 
al. Adult consequences of growth failure in early childhood–. The American Journal of 
Clinical Nutrition 2013; 98(5):1170-1178. 
15. WHO. WHO child growth standards: length/height for age, weight-for-age, weight-
for-length, weight-for-height and body mass index-for-age, methods and development. 
World Health Organization; 2006. 
16. WHO. Growth reference data for 5-19 years. WHO Reference 2007. World Health 
Organization; 2007. 
17. WHO. WHO case definitions of HIV for surveillance and revised clinical staging and 
immunological classification of HIV-related disease in adults and children. World Health 
Organization; 2007. 
18. Cole TJ, Donaldson MD, Ben-Shlomo Y. SITAR—a useful instrument for growth 
curve analysis. International Journal of Epidemiology 2010; 39(6):1558-1566. 
19. Granados A, Gebremariam A, Lee JM. Relationship between timing of peak height 
velocity and pubertal staging in boys and girls. Journal of Clinical Research in Pediatric 
Endocrinology 2015; 7(3):235. 
20. Tanner JM. Growth of the human at the time of adolescence. Lectures on the scientific 
basis of medicine 1953; 1:308. 
21. Working Group on Using Weight and Height References in Evaluating Growth Status of 
Thai Children. Manual on using weight and height references in evaluating the growth 
status of Thai children. Bangkok: Department of Health, Ministry of Public Health; 2000. 
22. Cole T, Cole MT. sitar: Super Imposition by Translation and Rotation Growth 
Curve Analysis. R package version 1.0.10. 2017. 
23. Portrait FRM, van Winderden TF, Deeg DJH. Early life undernutrition and adult 
height: The Dutch famine of 1944-45. Economics and Human Biology 2017 Nov;27(Pt 
B):339-348. 
24. Wagner IV, Sabin MA, Pfäffle RW, Hiemisch A, Sergeyev E, Körner A, et al. Effects of 
obesity on human sexual development. Nature Reviews Endocrinology 2012; 8(4):246. 
25. Mo-Suwan L, Choprapawon C. Comparison of Prevalence of Nutritional Status of 
Thai Children in the First 2 Years of Life Using National and International Growth 
Charts. J Med Assoc Thai 2016; 99(1):58-64. 
  
Tables and Figures 
Figure 1: Flow chart of participants included in the study 
 
Figure 2A: Mean height and growth velocity of females stratified by HAZ at ART initiation 
and 2B: mean height and growth velocity of females stratified by age at ART initiation 
 
 
 
Figure 3A: Mean height and growth velocity of males stratified by HAZ at ART initiation 
and 3B:  mean height and growth velocity of males stratified by age at ART initiation 
 
 
Table 1: Characteristics of 1094 young people living with HIV at ART initiation stratified by 
height-for age z-scores 
  Height-for-age z-score at ART initiation   
N(%) or 
median[IQR] 
All <-3 SD 
(Severely 
stunted 
   -3 to <-2 
SD (Stunted) 
   -2 to <-1 SD    >= -1 SD p-
value 
All 1094 157(14) 187(17) 272(25) 478(44)  
Male 526(48) 83(53) 90(48) 117(43) 236(49) 0.207 
Country       
   UK & Ireland 517(47) 17(11) 56(30) 137(50) 307(64) <0.00
1 
   Thailand 352(32) 121(77) 103(55) 84(31) 44(9)  
   Other* 225(21) 19(12) 28(15) 51(19) 127(27)  
Ethnicity       
   White 99(9) 10(6) 12(6) 26(10) 51(11) <0.00
1 
   Black 484(44) 16(10) 49(26) 125(46) 294(62)  
   Asian 365(33) 121(77) 106(57) 89(33) 49(10)  
   Other 63(6) 6(4) 5(3) 19(7) 33(7)  
   
Unknown/Prohib
ited 
83(8) 4(3) 15(8) 13(5) 51(11)  
Born abroad 370(35) 21(14) 51(28) 100(37) 198(43) <0.00
1 
Age        
   Median[IQR] 
years 
6.4[2.8,9.0] 6.4[2.7,9.0] 7.1[3.8,9.5] 6.4[3.2,8.7] 6.1[2.5,8.8] 0.236 
   1 to <3 years 280(26) 45(29) 35(19) 65(24) 135(28)  
   3 to <6  years 237(22) 31(20) 43(23) 64(24) 99(21)  
   6 to <11 years 577(53) 81(52) 109(58) 143(53) 244(51)  
Year started 
ART 
      
   Median[IQR] 2004[2003,20
07] 
2003[2003,20
08] 
2004[200,20
06] 
2004[2003,20
06] 
2005[2003,20
08] 
<0.00
1 
   <2004 433(40) 79(50) 78(42) 116(43) 160(33)  
   2004-2008 445(41) 69(44) 93(50) 106(39) 177(37)  
   >2008 216(20) 9(6) 16(9) 50(18) 141(30)  
NNRTI based  
regimen 
880(80) 141(90) 167(89) 222(82) 350(73) <0.00
1 
Viral load       
   Value present 980(90) 133(85) 167(89) 241(89) 439(92)  
   Median log VL  5.0[4.5,5.5] 5.3[4.9,5.7] 5.0[4.7,5.5] 5.0[4.5,5.4] 5.0[4.2,5.5] <0.00
1 
   <400 36(4) 4(3) 4(2) 6(2) 22(5)  
   >400 to 1,000 13(1) 1(1) 1(1) 1(0) 10(2)  
   >1,000 to 
10,000 
91(9) 7(5) 11(7) 21(9) 52(12)  
   >10,000 to 
100,000 
435(35) 39(29) 60(36) 89(27) 157(36)  
   >100,000 495(51) 82(62) 91(54) 124(51) 198(45)  
WHO 
immunological 
classification 
      
   Value present 1006(92) 145(92) 177(95) 258(95) 426(89)  
   None or not 
significant 
164(16) 7(5) 16(9) 40(16) 101(24) <0.00
1 
   Mild 110(11) 5(3) 12(7) 27(10) 66(15)  
   Advanced 129(13) 6(4) 12(7) 35(14) 76(18)  
   Severe 603(60) 127(88) 137(77) 156(60) 183(43)  
zBMI        
   Value present 1089(100) 157(100) 186(100) 271(100) 475(99)  
   Median zBMI -0.1[-1.1,0.8] -1.1[-2.3,0.2] -0.7[-1.6,0.3] -0.1[-0.9,0.7] 0.3[-0.5,1.1] <0.00
1 
   <-2 SD  
(Thinness) 
133(12) 49(31) 34(18) 22(8) 28(6)  
   -2 to <-1 SD 164(15) 32(20) 42(23) 42(16) 48(10)  
   -1 to <1 SD 576(53) 59(38) 96(62) 158(58) 263(55)  
    1 to <2 SD 
(Overweight) 
160(15) 13(8) 12(6) 37(14) 98(21)  
    >=2 SD 
(Obese) 
56(5) 4(3) 2(1) 12(4) 38(8)  
*Other includes Belgium, Greece, Latvia, Netherlands, Poland, Romania, Spain, Sweden and 
Switzerland 
 
Table 2: Association between  characteristics at ART initiation and average height, timing 
and shape of growth spurt after adjustment for baseline age and HAZ in 918 young people 
living with HIV 
 Average height Timing of growth spurt Shape of growth spurt 
 
coe
f 
95% 
CI 
p-
valu
e 
coe
f 
95% 
CI 
p-
valu
e 
coef 95% CI 
p-
valu
e 
Female 0.58 
-0.18, 
1.34 
0.13
2 
0.0
4 
-0.08, 
0.16 
0.48
5 
0.00
7 
-0.015, 
0.029 
0.55
5 
Country (ref: Other Europe)          
   Thailand 
-
3.0
6 
-4.34, -
1.78 
<0.0
01 
0.0
4 
-0.16, 
0.24 
0.70
1 
-
0.03
0 
-0.067, 
0.007 
0.11
6 
   UK & Ireland 
-
0.5
5 
-1.65, 
0.55 
0.32
5 
0.1
0 
-0.07, 
0.29 
0.24
1 
-
0.03
3 
-0.065, -
0.001 
0.04
4 
Year (ref: <2004)          
   2004 to <2008 
-
0.3
1 
-1.17, 
0.55 
0.47
6 
0.0
0 
-0.14, 
0.14 
0.99
1 
0.01
0 
-0.015, 
0.035 
0.42
6 
    >=2008 
-
0.2
2 
-1.33, 
0.90 
0.70
4 
-
0.0
8 
-0.26, 
0.10 
0.36
9 
0.01
1 
-0.022, 
0.043 
0.51
2 
NNRTI based regimen (ref: PI 
based regimen) 
0.2
7 
-0.78, 
1.31 
0.61
6 
-
0.0
4 
-0.20, 
0.13 
0.67
3 
-
0.01
8 
-0.048, 
0.012 
0.24
0 
Viral load (per log increase) 
-
0.1
0 
-0.51, 
0.30 
0.61
5 
0.0
3 
-0.03, 
0.10 
0.29
2 
-
0.00
2 
-0.013, 
0.010 
0.78
7 
WHO immunological classification 
(ref: None)         
   Mild 
-
0.1
0 
-1.56, 
1.35 
0.89
1 
0.0
6 
-0.17, 
0.29 
0.60
8 
-
0.00
3 
-0.045, 
0.039 
0.90
0 
   Advanced 
-
0.5
6 
-1.96, 
0.84 
0.43
3 
-
0.0
6 
-0.29, 
0.16 
0.58
1 
-
0.01
6 
-0.057, 
0.024 
0.42
6 
   Severe 0.2
8 
-0.84, 
1.39 
0.62
8 
-
0.0
1 
-0.18, 
0.17 
0.94
8 
-
0.00
2 
-0.034, 
0.031 
0.92
7 
zBMI (per 1SD increase) 
-
0.3
2 
-0.60, -
0.05 
0.02
1 
-
0.0
7 
-0.11, -
0.02 
0.00
3 
-
0.00
7 
-0.015, 
0.001 
0.08
3 
 
Note: Individual size, tempo and velocity parameters were estimated using the SITAR model 
described in the results and table S1 and represent the differences in size, tempo and velocity 
unexplained by age and HAZ at ART initiation. Model included data from 918 of the 1094 
children included in the SITAR model for which data on the explanatory variables were 
complete. 
